Pharma BD Deal Intelligence
GSK acquired clinical-stage Affinivax for $2.1B cash upfront plus up to $1.2B in development milestones (up to ~$3.3B total), closing 23 Aug 2022, to obtain the Multiple Antigen Presenting System (MAPS) vaccine platform and lead candidate AFX3772, a 24-valent pneumococcal vaccine, as a challenge to Pfizer's Prevnar franchise. On its Q3 2024 update (30 Oct 2024) GSK discontinued the 24-valent adult program (AFX3772), citing increased competition, and pivoted to a preclinical 30-plus-valent MAPS successor targeted to enter the clinic in 2025; a 24-valent pediatric program continued in Phase 2. The platform bet on MAPS remains in development; the originally acquired lead asset has been superseded.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Affinivax Inc. (this deal) | 2022 | $3.3B | 48 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2022 deals · GSK plc deals · Vaccines deals